Prasugrel HCl
产品说明书
 |
同义名 : | PCR 4099 hydrochloride;Prasugrel hydrochloride |
| CAS号 : | 389574-19-0 | |
| 货号 : | A529076 | |
| 分子式 : | C20H21ClFNO3S | |
| 纯度 : | 99% | |
| 分子量 : | 409.902 | |
| MDL号 : | MFCD11867705 | |
| 存储条件： |
粉末 Keep in dark place,Inert atmosphere,2-8°C 液体 -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : |
DMSO: 40 mg/mL(97.58 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO |
|
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | Prasugren HCl, irreversibly inhibits the P2Y12 receptors, inhibiting ADP-dependent platelet activation[3]. Prasugrel might have a better efficacy profile than ticagrelor in patients with ACS (acute coronary syndrome) undergoing PCI (percutaneous coronary intervention) [4]. In antiplatelet therapy after aneurysmal interventional therapy, the second generation of P2Y12 adenosine receptor antagonist prasugrel can significantly reduce the risk of thrombosis without increasing the risk of bleeding[5]. Laboratory studies and early phase clinical trials show prasugrel has a faster onset of action, is more potent and has reduced inter-patient response variability compared to clopidogrel[6]. Prasugrel and ticagrelor are more efficacious than clopidogrel in reducing the occurrence of non-fatal myocardial infarction, stroke, or cardiovascular (CV) death but they have also an increased risk of major bleeding in comparison to clopidogrel[7]. | ||
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
2.44mL 0.49mL 0.24mL |
12.20mL 2.44mL 1.22mL |
24.40mL 4.88mL 2.44mL |
| 参考文献 |
|---|